Tariq Musa sold $17K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $149.56 on 2026-11-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Nov 17, 2026, 10:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

This provides incremental transparency on director ownership but does not introduce new company fundamentals, guidance, or regulatory/clinical catalysts.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 framing and small dollar amount suggest limited trading impact.

03

What to watch

The sale size is small relative to typical institutional flows, and the plan is pre-arranged, which often means the timing is not information-driven.

Relevance 2/10Novelty 2/10Timing: filed 2026-11-17, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported from SEC EDGAR.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa sold 116 shares at $149.56 on 2026-11-16 under a pre-arranged 10b5-1 plan, totaling $17,348.96.

Expected impact

Likely limited price impact; any reaction should fade as the transaction is explicitly tied to a pre-arranged 10b5-1 plan.

Evidence & confidence

The filing is a small, director-level open-market sale with stated 10b5-1 pre-arrangement, which usually reduces interpretive weight versus discretionary selling.

Market effects

Minimal spillover to biotech/diagnostics peers; this is an individual insider transaction, not a sector catalyst.

No clear regional market linkage beyond US small-to-mid cap sentiment.

Low global relevance; no cross-border deal, regulation, or supply-chain shock described.

Counterpoint

Even with 10b5-1, repeated insider selling can be interpreted by some traders as a mild caution signal about near-term outlook.

Key entities

  • Guardant Health, Inc.

    US-listed company whose director insider sale is disclosed via SEC Form 4.

  • Tariq Musa

    Director who sold 116 shares under an open-market transaction code S, dated 2026-11-16.

  • Rule 10b5-1 plan

    Pre-arranged plan noted as Yes, which typically reduces information content of the sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.